Large biotech companies by CEO compensation 2019

Nota: La página que ha solicitado no está en su idioma predeterminado. Usted está usando nuestra plataforma en otro idioma ahora.

For the year 2019, the CEO of Vertex, Inc., Jeffrey Leiden, was awarded a compensation of roughly 19 million U.S. dollars. This statistic illustrates select CEO compensations provided by large biotech firms in 2019. Vertex Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts.

Select CEO compensations provided by large biotech companies in 2019 (in million U.S. dollars)

Company name (CEO name)	Compensation in million U.S. dollars
Gilead (Daniel O'Day)	29.11
AbbVie (Rick Gonzalez)	21.61
Regeneron (Leonard Schleifer)	21.46
Amgen (Robert Brwadway)	19.61
Vertex (Jeffrey Leiden)	18.79
BioMarin (Jean-Jacques Bienaime)	18.41
Biogen (Michel Vounatsos)	18.16

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

September 2020

More information

Region

Worldwide

Survey time period

2019

Number of respondents

base: 231 life sciences companies

Special properties

large biotech companies

Supplementary notes

For the report, BioPharma Dive segmented the 231 companies into four groups by number of employees: small (fewer than 200), mid-sized (200 to 999), large (1,000 to 9,999) and greater than 10,000 (giant).

This statistic is for firms in the third and fourth category: large and giant biotech companies with more than one thousand employees.

CEO compensation includes base salary, cash bonuses and long-term stock and option awards, as described in annual proxy filings.

Citation formats